Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARLA-M19: CD19 CAR-T Cells in R/R AML
NCT06649227Phase 1Recruiting
- Sponsor
- CHU de Lille
- Start
- Jul 2025
- Primary completion
- Jul 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in acute myeloid leukemia (AML), sponsored by CHU de Lille. Primary endpoint: Number of patients deceased without progression at 1 month. Started Jul 2025; status: recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06649227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649227.